Abstract: Triple negative breast cancer (TNBC) as the most aggressive subtype of breast cancer, is characterized by high recurrence rate, high mortality, and few treatment methods. RNA interference (RNAi) therapy can efficiently regulate target genes and related downstream pathways, and combined with chemotherapy drugs, improving therapy of TNBC, which is of great significance for gene regulation and disease treatment. However, RNA is easily degraded by nucleases, recognized by the immune system, and is difficult to transport across membranes. Therefore, designing precise targeting drug delivery systems is an important goal in the development of RNA drugs. The paper provides a comprehensive review of the anti-TNBC RNA drug delivery system and offers insights into its future development direction, aiming to serve as a valuable reference for RNA drug research and development, as well as to facilitate the clinical translation of RNA drugs.